Myeloproliferative Neoplasms

Latest News

FDA Approves Momelotinib to Treat Myelofibrosis With Anemia
FDA Approves Momelotinib to Treat Myelofibrosis With Anemia

September 15th 2023

The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.

blood cells
Jaktinib Emerges As Potentially Effective Treatment for Patients With Ruxolitinib-Intolerant Myelofibrosis

July 2nd 2023

Spleen Volume Reduction Associated With Overall Survival Benefit in Patients With Myelofibrosis Receiving Pacritinib
Spleen Volume Reduction Associated With Overall Survival Benefit in Patients With Myelofibrosis Receiving Pacritinib

June 29th 2023

blood cells
Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs

April 27th 2023

Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera
Ruxolitinib Reduces Hematocrit Levels in 6-Month Analysis of Patients With Polycythemia Vera

March 9th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.